$INTI
Inhibitor Therapeutics, Inc.

2016 Q1 Form 10-K Financial Statement

#000119312516446037 Filed on February 01, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $610.0K $2.269M $590.0K
YoY Change 0.0% 50.58% 195.0%
% of Gross Profit
Research & Development $582.5K $1.680M $310.0K
YoY Change 86.1% -30.87% 1450.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.194M $3.950M $900.0K
YoY Change 29.46% 0.3% 328.57%
Operating Profit -$1.194M -$3.950M
YoY Change 29.46% 0.3%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.190M -$3.950M -$900.0K
YoY Change 29.35% -0.65% 309.09%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.194M -$3.950M -$900.0K
YoY Change 29.46% -0.65% 309.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$16.98K $0.00
COMMON SHARES
Basic Shares Outstanding 245.4M shares 211.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $120.0K $601.5K $370.0K
YoY Change 50.0% 64.71%
Cash & Equivalents $118.6K $601.5K $365.2K
Short-Term Investments
Other Short-Term Assets $52.02K $34.41K $97.82K
YoY Change 18.97% -64.82%
Inventory
Prepaid Expenses $97.82K
Receivables
Other Receivables
Total Short-Term Assets $170.6K $635.9K $463.0K
YoY Change 33.65% 37.34% 4431.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K $0.00
YoY Change
Total Long-Term Assets $250.0K $250.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $170.6K $635.9K $463.0K
Total Long-Term Assets $250.0K $250.0K $0.00
Total Assets $420.6K $885.9K $463.0K
YoY Change 229.46% 91.34% 4431.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $647.1K $383.4K $325.0K
YoY Change 31.03% 17.97% 13.2%
Accrued Expenses $23.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $743.4K $461.9K $400.9K
YoY Change 30.76% 15.21% -48.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $743.4K $461.9K $400.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $743.4K $461.9K $400.9K
YoY Change 30.76% 15.21% -48.34%
SHAREHOLDERS EQUITY
Retained Earnings -$37.37M -$32.22M
YoY Change 12.74% 14.07%
Common Stock $37.04M $32.29M
YoY Change 13.27% 1709007.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$322.8K $424.0K $62.08K
YoY Change
Total Liabilities & Shareholders Equity $420.6K $885.9K $463.0K
YoY Change 229.46% 91.34% 4431.45%

Cashflow Statement

Concept 2016 Q1 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$1.194M -$3.950M -$900.0K
YoY Change 29.46% -0.65% 309.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$480.0K -$2.264M -$520.0K
YoY Change 71.43% 73.66% 205.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.500M
YoY Change 66.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.500M 510.0K
YoY Change 49.84% 200.0%
NET CHANGE
Cash From Operating Activities -480.0K -2.264M -520.0K
Cash From Investing Activities
Cash From Financing Activities 2.500M 510.0K
Net Change In Cash -480.0K 236.3K -10.00K
YoY Change 71.43% -35.26%
FREE CASH FLOW
Cash From Operating Activities -$480.0K -$2.264M -$520.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
340 shares
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
245353270 shares
CY2015Q2 dei Entity Public Float
EntityPublicFloat
2019916
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32263890
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75933
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
324966
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32222953
CY2014Q4 us-gaap Liabilities
Liabilities
400899
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462978
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
400899
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2164708
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
17850
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
878706
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2164708
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
256219
CY2014Q4 us-gaap Assets
Assets
462978
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Assets Current
AssetsCurrent
462978
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
97817
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15779
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
996154
CY2014Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36571982
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
423979
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78524
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
383356
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36172538
CY2015Q4 us-gaap Liabilities
Liabilities
461880
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
885859
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
461880
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3597290
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
17850
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1681549
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3597290
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
841524
CY2015Q4 us-gaap Assets
Assets
885859
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
635859
CY2015Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
213000
CY2015Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
34414
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
60213
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
996154
CY2015Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
CY2015Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1303524
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95884524 shares
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
105170
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-3975298
CY2014 us-gaap Revenues
Revenues
0
CY2014 us-gaap Interest Paid
InterestPaid
2005
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-3937817
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
450000
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
87817
CY2014 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
619134
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
753585
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
236284
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
753585
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
80899
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
364944
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1407921
CY2014 us-gaap Operating Expenses
OperatingExpenses
3937817
CY2014 us-gaap Interest Expense
InterestExpense
37481
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1668468
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2430735
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1500000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1507082
CY2014 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
61327
CY2014 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1351601
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-137219
CY2014 hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
CY2014 hppi Collection Of Stock Subscription Receivable
CollectionOfStockSubscriptionReceivable
1250000
CY2014 hppi Issuance Of Preferred Stock
IssuanceOfPreferredStock
1290726
CY2014 hppi Stock Issued During Period Value Debt Forgiveness
StockIssuedDuringPeriodValueDebtForgiveness
189768
CY2014 hppi Noncash Interest Expense
NoncashInterestExpense
34819
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2263716
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2015 dei Trading Symbol
TradingSymbol
HPPI
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
232616649 shares
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-3949585
CY2015 us-gaap Revenues
Revenues
0
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2500000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-3949585
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
250000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-63403
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1721485
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1721485
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
20950
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1458241
CY2015 us-gaap Operating Expenses
OperatingExpenses
3949585
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1680250
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1342859
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-136332
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2269335
CY2015 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
150981
CY2015 hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000

Files In Submission

Name View Source Status
0001193125-16-446037-index-headers.html Edgar Link pending
0001193125-16-446037-index.html Edgar Link pending
0001193125-16-446037.txt Edgar Link pending
0001193125-16-446037-xbrl.zip Edgar Link pending
d113219d10k.htm Edgar Link pending
d113219dex311.htm Edgar Link pending
d113219dex312.htm Edgar Link pending
d113219dex321.htm Edgar Link pending
d113219dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20151231.xml Edgar Link completed
hppi-20151231.xsd Edgar Link pending
hppi-20151231_cal.xml Edgar Link unprocessable
hppi-20151231_def.xml Edgar Link unprocessable
hppi-20151231_lab.xml Edgar Link unprocessable
hppi-20151231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending